MedTrace Logo

Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status

NCT02076503 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-01-05

No results posted yet for this study

Summary

Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment, accurate staging of the disease at the time point of diagnosis is important. The objective of this study is to evaluate the diagnostic potential of a combined PET/MR examination for risk assessment and detection of lymph node metastases. The overall aim of the project is to improve the investigators ability to provide individually tailored treatment to prostate cancer patients.

The study will include 32 men with high-risk prostate cancer, who are eligible for radical prostatectomy. Informed consent is a requirement for inclusion in the study.

Conditions

  • Prostatic Neoplasms

Interventions

PROCEDURE

PET-MR 18f-FACBC

PROCEDURE

histology (gold standard)

histopathological classification of co-located dissected lymph nodes

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    collaborator OTHER

  • Norwegian Cancer Society

    collaborator OTHER

  • St. Olavs Hospital

    lead OTHER

Principal Investigators

  • Anders Angelsen, prof · St. Olavs Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02076503 on ClinicalTrials.gov